Anti-dementia Drugs for Psychopathology and Cognitive Impairment in Schizophrenia: A Systematic Review and Meta-analysis

The International Journal of Neuropsychopharmacology
Taro KishiNakao Iwata

Abstract

We conducted a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials of anti-dementia drugs plus antipsychotics (ADD+AP) for schizophrenia. Primary outcomes of efficacy and safety included improving overall symptoms (Positive and Negative Syndrome Scale and Brief Psychiatric Rating Scale scores) and all-cause discontinuation, respectively. Other outcomes included psychopathology subscales (positive, negative, general, and anxiety/depressive symptoms), cognitive function (attention/vigilance, reasoning/problem solving, social cognition, speed of processing, verbal learning, visual learning, working memory, and cognitive control/executive function), Mini-Mental State Examination (MMSE) scores, treatment discontinuation due to adverse events and inefficacy, and individual adverse events. We evaluated the effect size using a random effects model. We identified 37 studies (n=1,574): 14 donepezil-based (n=568), 10 galantamine-based (n=371), 4 rivastigmine-based (n=146), and 9 memantine-based (n=489) studies. Pooled ADD+AP treatments were superior to placebo+AP in improving the overall symptoms (24 studies, 1,069 patients: standardized mean difference [SMD]=-0.34, 95% confidence interval [CI]=-0.61...Continue Reading

References

Nov 1, 1975·Journal of Psychiatric Research·M F FolsteinP R McHugh
Jul 1, 1982·Archives of General Psychiatry·N C Andreasen
Aug 21, 1997·The New England Journal of Medicine·J LeLorierF Derderian
Aug 3, 2005·Clinical Neuropharmacology·Steven K EricksonGregory A Light
Jul 13, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Richard S E KeefeRobert Goldman
Oct 18, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·W Wolfgang Fleischhacker, Georg Kemmler
Nov 29, 2007·Expert Opinion on Investigational Drugs·Mercedes VillarroyaManuela G López
Jun 24, 2008·Schizophrenia Research·Kristi A SaccoTony P George
Nov 14, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jeffrey A LiebermanUNKNOWN MEM-MD-29 Study Group
Apr 2, 2009·The British Journal of Psychiatry : the Journal of Mental Science·D VelakoulisC McLean
Jul 23, 2009·BMJ : British Medical Journal·David MoherUNKNOWN PRISMA Group
Aug 25, 2009·Lancet·Jim van Os, Shitij Kapur
Nov 10, 2012·Acta Psychiatrica Scandinavica·F U LangM Jäger
Sep 4, 2013·The British Journal of Psychiatry : the Journal of Mental Science·Kee-Hong ChoiMatthew M Kurtz
Jun 13, 2015·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Neal R SwerdlowGregory A Light
Feb 28, 2016·Lancet·Philip ScheltensWiesje Maria Van der Flier
Mar 10, 2016·Harvard Review of Psychiatry·Urs HeilbronnerThomas G Schulze
Jun 1, 2017·Asian Journal of Psychiatry·Vijay KumarBangalore N Gangadhar

❮ Previous
Next ❯

Citations

Dec 4, 2019·Psychopharmacology·Timothy TanzerCatarina Drumonde Melo
Jul 20, 2019·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·L HolperJ J Mann

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here